中国全科医学 ›› 2020, Vol. 23 ›› Issue (3): 362-368.DOI: 10.12114/j.issn.1007-9572.2019.00.251
张楠1,2,朱华栋1,2*
出版日期:
2020-01-20
发布日期:
2020-01-20
ZHANG Nan1,2,ZHU Huadong1,2*
Published:
2020-01-20
Online:
2020-01-20
摘要: 益生菌被认为是对宿主健康有益的活生物体。近年来,益生菌逐渐成为临床上常用的处方,被广泛用于治疗胃肠道疾病和非胃肠道疾病,然而评估其疗效的相关临床研究结果通常是相互矛盾的。目前仍有大量临床研究探讨益生菌在治疗胃肠道疾病方面的作用,但对于很多疾病仍无统一定论。本文回顾了近年来益生菌在不同病因所致腹泻中的作用,主要包括感染性腹泻、抗生素相关性腹泻或难辨梭菌相关性腹泻、腹泻型肠易激综合征等,指出了益生菌对不同疾病、人群中所出现腹泻的临床应用价值及益生菌使用中可能存在的潜在风险,从而为其今后进一步临床研究及应用提供依据。
[1]SOMMER F,B?CKHED F.The gut microbiota——masters of host development and physiology[J].Nat Rev Micro,2013,11(4):227-238.DOI:10.1038/nrmicro2974. [2]SáNCHEZ B,DELGADO S,BLANCO-MíGUEZ A,et al.Probiotics,gut microbiota,and their influence on host health and disease[J].Mol Nutr Food Res,2017,61(1).[Epub ahead of print].DOI:10.1002/mnfr.201600240. [3]MORELLI L,CAPURSO L.FAO/WHO guidelines on probiotics:10 years later[J].J Clin Gastroenterol,2012,46(Suppl):S1-2.DOI:10.1097/MCG.0b013e318269fdd5. [4]KORETZ R L.Probiotics in gastroenterology:how pro is the evidence in adults?[J].Am J Gastroenterol,2018,113(8):1125-1136.DOI:10.1038/s41395-018-0138-0. [5]LIU Y Y,TRAN D Q,RHOADS J M.Probiotics in disease prevention and treatment[J].J Clin Pharmacol,2018,58(Suppl 10):S164-179.DOI:10.1002/jcph.1121. [6]VALDOVINOS M A,MONTIJO E,ABREU A T,et al.The Mexican consensus on probiotics in gastroenterology[J].Rev Gastroenterol Mex,2017,82(2):156-178.DOI:10.1016/j.rgmx.2016.08.004. [7]袁莉娟,刘爱民,李艺,等.微生态制剂的应用研究进展[J].临床合理用药杂志,2018,11(15):178-181.DOI:10.15887/j.cnki.13-1389/r.2018.15.088. YUAN L J,LIU A M,LI Y,et al.Application and research progress of microecologics[J].Chinese Journal of Clinical Rational Drug Use,2018,11(15):178-181.DOI:10.15887/j.cnki.13-1389/r.2018.15.088. [8]GUERRANT R L,VAN GILDER T,STEINER T S,et al.Practice guidelines for the management of infectious diarrhea[J].Clin Infect Dis,2001,32(3):331-351.DOI:10.1086/318514. [9]SURAWICZ C M.Mechanisms of diarrhea[J].Curr Gastroenterol Rep,2010,12(4):236-241.DOI:10.1007/s11894-010-0113-4. [10]孙笑非,温俊.益生菌调节肠道菌群的作用机制及研究进展[J].饲料研究,2010(4):56-58.DOI:10.13557/j.cnki.issn1002-2813.2010.04.020. [11]DICKINSON B,SURAWICZ C M.Infectious diarrhea:an overview[J].Curr Gastroenterol Rep,2014,16(8):399.DOI:10.1007/s11894-014-0399-8. [12]ANAND S,MANDAL S,PATIL P,et al.Pathogen-induced secretory diarrhea and its prevention[J].Eur J Clin Microbiol Infect Dis,2016,35(11):1721-1739.DOI:10.1007/s10096-016-2726-5. [13]GUARINO A,ALBANO F,ASHKENAZI S,et al.European Society for Paediatric Gastroenterology,Hepatology,and Nutrition/European Society for Paediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe:executive summary[J].J Pediatr Gastroenterol Nutr,2008,46(5):619-621.DOI:10.1097/MPG.0b013e31816e219e. [14]WILKINS T,SEQUOIA J.Probiotics for gastrointestinal conditions:a summary of the evidence[J].Am Fam Physician,2017,96(3):170-178. [15]HILL C,GUARNER F,REID G,et al.The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic[J].Nat Rev Gastroenterol Hepatol,2014,11(8):506-514.DOI:10.1038/nrgastro.2014.66. [16]LEE H J,CHOI J K,RYU H S,et al.Therapeutic modulation of gut microbiota in functional bowel disorders[J].J Neurogastroenterol Motil,2017,23(1):9-19.DOI:10.5056/jnm16124. [17]BRON P A,KLEEREBEZEM M,BRUMMER R J,et al.Can probiotics modulate human disease by impacting intestinal barrier function?[J].Br J Nutr,2017,117(1):93-107.DOI:10.1017/S0007114516004037. [18]BUTEL M J.Probiotics,gut microbiota and health[J].Med Mal Infect,2014,44(1):1-8.DOI:10.1016/j.medmal.2013.10.002. [19]SENOK A C,ISMAEEL A Y,BOTTA G A.Probiotics:facts and myths[J].Clin Microbiol Infect,2005,11(12):958-966.DOI:10.1111/j.1469-0691.2005.01228.x. [20]OELSCHLAEGER T A.Mechanisms of probiotic actions——a review[J].Int J Med Microbiol,2010,300(1):57-62.DOI:10.1016/j.ijmm.2009.08.005. [21]ABRAHAM B P,QUIGLEY E M M.Probiotics in inflammatory bowel disease[J].Gastroenterol Clin North Am,2017,46(4):769-782.DOI:10.1016/j.gtc.2017.08.003. [22]SCARPELLINI E,CAZZATO A,LAURITANO C,et al.Probiotics:which and when?[J].Dig Dis,2008,26(2):175-182.DOI:10.1159/000116776. [23]SáNCHEZ B,DE LOS REYES-GAVILáN C G,MARGOLLES A,et al.Probiotic fermented milks:present and future[J].International Journal of Dairy Technology,2009,62(4):472-483.DOI:10.1111/j.1471-0307.2009.00528.x. [24]SZAJEWSKA H,KOLODZIEJ M.Systematic review with meta-analysis:Lactobacillus rhamnosus GG in the prevention of antibiotic-associated diarrhoea in children and adults[J].Aliment Pharmacol Ther,2015,42(10):1149-1157.DOI:10.1111/apt.13404. [25]BEGOVIC B,AHMEDTAGIC S,CALKIC L,et al.Open clinical trial on using nifuroxazide compared to probiotics in treating acute diarrhoeas in adults[J].Mater Sociomed,2016,28(6):454-458.DOI:10.5455/msm.2016.28.454-458. [26]SASAKI Y,MURAKAMI Y,ZAI H,et al.Effect of antibiotics for infectious diarrhea on the duration of hospitalization:a retrospective cohort study at a single center in Japan from 2012 to 2015[J].J Infect Chemother,2018,24(1):59-64.DOI:10.1016/j.jiac.2017.09.004. [27]SHARIF A,KASHANI H H,NASRI E,et al.The role of probiotics in the treatment of dysentery:a randomized double-blind clinical trial[J].Probiotics Antimicrob Proteins,2017,9(4):380-385.DOI:10.1007/s12602-017-9271-0. [28]BAE J M.Prophylactic efficacy of probiotics on travelers' diarrhea:an adaptive meta-analysis of randomized controlled trials[J].Epidemiol Health,2018,40:e2018043.DOI:10.4178/epih.e2018043. [29]MCFARLAND L V,GOH S.Are probiotics and prebiotics effective in the prevention of travellers' diarrhea:a systematic review and meta-analysis[J].Travel Med Infect Dis,2019,27:11-19.DOI:10.1016/j.tmaid.2018.09.007. [30]EVANS D P.Non-pharmacotherapeutic interventions in travellers diarrhoea(TD)[J].J Travel Med,2018,25(suppl_1):S38-45.DOI:10.1093/jtm/tay013. [31]HAN Y,LENG Y X,YAO G Q.Effects of antibiotics on intestinal microflora and intestinal mucosal barrier function and its mechanisms[J].Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,2017,29(11):1047-1051.DOI:10.3760/cma.j.issn.2095-4352.2017.11.019. [32]DIETRICH C G,KOTTMANN T,ALAVI M.Commercially available probiotic drinks containing Lactobacillus casei DN-114001 reduce antibiotic-associated diarrhea[J].World J Gastroenterol,2014,20(42):15837-15844.DOI:10.3748/wjg.v20.i42.15837. [33]ALLEN S J,WAREHAM K,WANG D,et al.A high-dose preparation of lactobacilli and bifidobacteria in the prevention of antibiotic-associated and Clostridium difficile diarrhoea in older people admitted to hospital:a multicentre,randomised,double-blind,placebo-controlled,parallel arm trial(PLACIDE)[J].Health Technol Assess,2013,17(57):1-140.DOI:10.3310/hta17570. [34]MCFARLAND L V,OZEN M,DINLEYICI E C,et al.Comparison of pediatric and adult antibiotic-associated diarrhea and Clostridium difficile infections[J].World J Gastroenterol,2016,22(11):3078-3104.DOI:10.3748/wjg.v22.i11.3078. [35]AGAMENNONE V,KRUL C A M,RIJKERS G,et al.A practical guide for probiotics applied to the case of antibiotic-associated diarrhea in The Netherlands[J].BMC Gastroenterol,2018,18(1):103.DOI:10.1186/s12876-018-0831-x. [36]CAI J Y,ZHAO C Y,DU Y J,et al.Comparative efficacy and tolerability of probiotics for antibiotic-associated diarrhea:systematic review with network meta-analysis[J].United European Gastroenterol J,2018,6(2):169-180.DOI:10.1177/2050640617736987. [37]ZHANG D M,XU B B,YU L,et al.A prospective control study of Saccharomyces Boulardii in prevention of antibiotic-associated diarrhea in the older inpatients[J].Zhonghua Nei Ke Za Zhi,2017,56(6):398-401.DOI:10.3760/cma.j.issn.0578-1426.2017.06.003. [38]WAN C M,YU H,LIU G,et al.A multicenter randomized controlled study of Saccharomyces Boulardii in the prevention of antibiotic-associated diarrhea in infants and Young children[J].Chinese Journal of Pediatrics,2017,55(5):349-354.DOI:10.3760/cma.j.issn.0578-1310.2017.05.008. [39]BLAABJERG S,ARTZI D M,AABENHUS R.Probiotics for the prevention of antibiotic-associated diarrhea in outpatients——a systematic review and meta-analysis[J].Antibiotics(Basel),2017,6(4):E21.DOI:10.3390/antibiotics6040021. [40]HAYES S R,VARGAS A J.Probiotics for the prevention of pediatric antibiotic-associated diarrhea[J].Explore(NY),2016,12(6):463-466.DOI:10.1016/j.explore.2016.08.015. [41]SZAJEWSKA H,KOLODZIEJ M.Systematic review with meta-analysis:saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea[J].Aliment Pharmacol Ther,2015,42(7):793-801.DOI:10.1111/apt.13344. [42]SZAJEWSKA H,CANANI R B,GUARINO A,et al.Probiotics for the prevention of antibiotic-associated diarrhea in children[J].J Pediatr Gastroenterol Nutr,2016,62(3):495-506.DOI:10.1097/MPG.0000000000001081. [43]EHRHARDT S,GUO N,HINZ R,et al.Saccharomyces boulardii to prevent antibiotic-associated diarrhea:a randomized,double-masked,placebo-controlled trial[J].Open Forum Infect Dis,2016,3(1):ofw011.DOI:10.1093/ofid/ofw011. [44]VERNAYA M,MCADAM J,HAMPTON M D.Effectiveness of probiotics in reducing the incidence of Clostridium difficile-associated diarrhea in elderly patients:a systematic review[J].JBI Database System Rev Implement Rep,2017,15(1):140-164.DOI:10.11124/JBISRIR-2016-003234. [45]JAFARNEJAD S,SHAB-BIDAR S,SPEAKMAN J R,et al.Probiotics reduce the risk of antibiotic-associated diarrhea in adults(18-64 years)but not the elderly(>65 years):a meta-analysis[J].Nutr Clin Pract,2016,31(4):502-513.DOI:10.1177/0884533616639399. [46]XIE C,LI J,WANG K,et al.Probiotics for the prevention of antibiotic-associated diarrhoea in older patients:a systematic review[J].Travel Med Infect Dis,2015,13(2):128-134.DOI:10.1016/j.tmaid.2015.03.001. [47]WRIGHT K,WRIGHT H,MURRAY M.Probiotic treatment for the prevention of antibiotic-associated diarrhoea in geriatric patients:a multicentre randomised controlled pilot study[J].Australas J Ageing,2015,34(1):38-42.DOI:10.1111/ajag.12116. [48]LACY B E.Review article:an analysis of safety profiles of treatments for diarrhoea-predominant irritable bowel syndrome[J].Aliment Pharmacol Ther,2018,48(8):817-830.DOI:10.1111/apt.14948. [49]ISHAQUE S M,KHOSRUZZAMAN S M,AHMED D S,et al.A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation(Bio-Kult?)in the management of diarrhea-predominant irritable bowel syndrome[J].BMC Gastroenterol,2018,18(1):71.DOI:10.1186/s12876-018-0788-9. [50]HAN K,WANG J,SEO J G,et al.Efficacy of double-coated probiotics for irritable bowel syndrome:a randomized double-blind controlled trial[J].J Gastroenterol,2017,52(4):432-443.DOI:10.1007/s00535-016-1224-y. [51]YOON H,PARK Y S,LEE D H,et al.Effect of administering a multi-species probiotic mixture on the changes in fecal microbiota and symptoms of irritable bowel syndrome:a randomized,double-blind,placebo-controlled trial[J].J Clin Biochem Nutr,2015,57(2):129-134.DOI:10.3164/jcbn.15-14. [52]STAUDACHER H M,WHELAN K.Altered gastrointestinal microbiota in irritable bowel syndrome and its modification by diet:probiotics,prebiotics and the low FODMAP diet[J].Proc Nutr Soc,2016,75(3):306-318.DOI:10.1017/S0029665116000021. [53]SUN Y Y,LI M,LI Y Y,et al.The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome:a randomized,double-blind,placebo-controlled trial[J].Sci Rep,2018,8(1):2964.DOI:10.1038/s41598-018-21241-z. [54]SHIN S P,CHOI Y M,KIM W H,et al.A double blind,placebo-controlled,randomized clinical trial that breast milk derived-Lactobacillus Gasseri BNR17 mitigated diarrhea-dominant irritable bowel syndrome[J].J Clin Biochem Nutr,2018,62(2):179-186.DOI:10.3164/jcbn.17-73. [55]ABBAS Z,YAKOOB J,JAFRI W,et al.Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome:a randomized trial[J].Eur J Gastroenterol Hepatol,2014,26(6):630-639.DOI:10.1097/MEG.0000000000000094. [56]FORD A C,QUIGLEY E M,LACY B E,et al.Efficacy of prebiotics,probiotics,and synbiotics in irritable bowel syndrome and chronic idiopathic constipation:systematic review and meta-analysis[J].Am J Gastroenterol,2014,109(10):1547-1561;quiz 1546,1562.DOI:10.1038/ajg.2014.202. [57]ZHANG Y,LI L X,GUO C G,et al.Effects of probiotic type,dose and treatment duration on irritable bowel syndrome diagnosed by Rome Ⅲ criteria:a meta-analysis[J].BMC Gastroenterol,2016,16(1):62.DOI:10.1186/s12876-016-0470-z. [58]HOD K,SPERBER A D,RON Y,et al.A double-blind,placebo-controlled study to assess the effect of a probiotic mixture on symptoms and inflammatory markers in women with diarrhea-predominant IBS[J].Neurogastroenterol Motil,2017,29(7).[Epub ahead of print].DOI:10.1111/nmo.13037. [59]GANJI-ARJENAKI M,RAFIEIAN-KOPAEI M.Probiotics are a good choice in remission of inflammatory bowel diseases:a meta analysis and systematic review[J].J Cell Physiol,2018,233(3):2091-2103.DOI:10.1002/jcp.25911. [60]DURCHSCHEIN F,PETRITSCH W,HAMMER H F.Diet therapy for inflammatory bowel diseases:the established and the new[J].World J Gastroenterol,2016,22(7):2179-2194.DOI:10.3748/wjg.v22.i7.2179. [61]DERWA Y,GRACIE D J,HAMLIN P J,et al.Systematic review with meta-analysis:the efficacy of probiotics in inflammatory bowel disease[J].Aliment Pharmacol Ther,2017,46(4):389-400.DOI:10.1111/apt.14203. [62]DIGNASS A,LINDSAY J O,STURM A,et al.Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2:current management[J].J Crohns Colitis,2012,6(10):991-1030.DOI:10.1016/j.crohns.2012.09.002. [63]LOSURDO G,IANNONE A,CONTALDO A,et al.Escherichia coli nissle 1917 in ulcerative colitis treatment:systematic review and meta-analysis[J].J Gastrointestin Liver Dis,2015,24(4):499-505.DOI:10.15403/jgld.2014.1121.244.ecn. [64]SHEN J,ZUO Z X,MAO A P.Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis,Crohn's disease,and pouchitis:meta-analysis of randomized controlled trials[J].Inflamm Bowel Dis,2014,20(1):21-35.DOI:10.1097/01.MIB.0000437495.30052.be. [65]TAMAKI H,NAKASE H,INOUE S,et al.Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis:a randomized,double-blinded,placebo-controlled multicenter trial[J].Dig Endosc,2016,28(1):67-74.DOI:10.1111/den.12553. [66]YOSHIMATSU Y,YAMADA A,FURUKAWA R,et al.Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis[J].World J Gastroenterol,2015,21(19):5985-5994.DOI:10.3748/wjg.v21.i19.5985. [67]PALUMBO V D,ROMEO M,MARINO GAMMAZZA A,et al.The long-term effects of probiotics in the therapy of ulcerative colitis:a clinical study[J].Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub,2016,160(3):372-377.DOI:10.5507/bp.2016.044. [68]THOMSEN M,CLARKE S,VITETTA L.The role of adjuvant probiotics to attenuate intestinal inflammatory responses due to cancer treatments[J].Benef Microbes,2018:1-18.DOI:10.3920/BM2017.0172. [69]WEI D,HEUS P,VAN DE WETERING F T,et al.Probiotics for the prevention or treatment of chemotherapy- or radiotherapy-related diarrhoea in people with cancer[J].Cochrane Database Syst Rev,2018,8:CD008831.DOI:10.1002/14651858.CD008831.pub3. [70]LINN Y H,THU K K,WIN N H H.Effect of probiotics for the prevention of acute radiation-induced diarrhoea among cervical cancer patients:a randomized double-blind placebo-controlled study[J].Probiotics Antimicrob Proteins,2018.[Epub ahead of print].DOI:10.1007/s12602-018-9408-9. [71]DEMERS M,DAGNAULT A,DESJARDINS J.A randomized double-blind controlled trial:impact of probiotics on diarrhea in patients treated with pelvic radiation[J].Clin Nutr,2014,33(5):761-767.DOI:10.1016/j.clnu.2013.10.015. [72]LIU M M,LI S T,SHU Y,et al.Probiotics for prevention of radiation-induced diarrhea:a meta-analysis of randomized controlled trials[J].PLoS One,2017,12(6):e0178870.DOI:10.1371/journal.pone.0178870. [73]WANG Y H,YAO N,WEI K K,et al.The efficacy and safety of probiotics for prevention of chemoradiotherapy-induced diarrhea in people with abdominal and pelvic cancer:a systematic review and meta-analysis[J].Eur J Clin Nutr,2016,70(11):1246-1253.DOI:10.1038/ejcn.2016.102. [74]WARDILL H R,VAN SEBILLE Y Z A,CIORBA M A,et al.Prophylactic probiotics for cancer therapy-induced diarrhoea:a meta-analysis[J].Curr Opin Support Palliat Care,2018,12(2):187-197.DOI:10.1097/SPC.0000000000000338. [75]SHIMIZU K,OGURA H,KABATA D,et al.Association of prophylactic synbiotics with reduction in diarrhea and pneumonia in mechanically ventilated critically ill patients:a propensity score analysis[J].J Infect Chemother,2018,24(10):795-801.DOI:10.1016/j.jiac.2018.06.006. [76]CULPEPPER T,CHRISTMAN M C,NIEVES C Jr,et al.Bifidobacterium bifidum R0071 decreases stress-associated diarrhoea-related symptoms and self-reported stress:a secondary analysis of a randomised trial[J].Benef Microbes,2016,7(3):327-336.DOI:10.3920/BM2015.0156. [77]ZHAO R,WANG Y,HUANG Y Q,et al.Effects of fiber and probiotics on diarrhea associated with enteral nutrition in gastric cancer patients:a prospective randomized and controlled trial[J].Medicine(Baltimore),2017,96(43):e8418.DOI:10.1097/MD.0000000000008418. [78]DE CASTRO SOARES G G,MARINHO C H,PITOL R,et al.Sporulated Bacillus as alternative treatment for diarrhea of hospitalized adult patients under enteral nutrition:a pilot randomized controlled study[J].Clin Nutr ESPEN,2017,22:13-18.DOI:10.1016/j.clnesp.2017.08.006. [79]PANIGRAHI P,PARIDA S,PRADHAN L,et al.Long-term colonization of a Lactobacillus plantarum synbiotic preparation in the neonatal gut[J].J Pediatr Gastroenterol Nutr,2008,47(1):45-53.DOI:10.1097/MPG.0b013e31815a5f2c. [80]MU?OZ P,BOUZA E,CUENCA-ESTRELLA M,et al.Saccharomyces cerevisiae fungemia:an emerging infectious disease[J].Clin Infect Dis,2005,40(11):1625-1634.DOI:10.1086/429916. [81]SALMINEN M K,RAUTELIN H,TYNKKYNEN S,et al.Lactobacillus bacteremia,clinical significance,and patient outcome,with special focus on probiotic L.rhamnosus GG[J].Clin Infect Dis,2004,38(1):62-69.DOI:10.1086/380455. [82]孙雯娟,张波,李大魁,等.益生菌制剂的发展现状与临床应用进展[J].中国医院药学杂志,2015,35(9):850-857.DOI:10.13286/j.cnki.chinhosppharmacyj.2015.09.22. SUN W J,ZHANG B,LI D K,et al.Development status and clinical application progress of probiotic preparations[J].Chinese Journal of Hospital Pharmacy,2015,35(9):850-857.DOI:10.13286/j.cnki.chinhosppharmacyj.2015.09.22. [83]HUNGIN A P S,MITCHELL C R,WHORWELL P,et al.Systematic review:probiotics in the management of lower gastrointestinal symptoms - an updated evidence-based international consensus[J].Aliment Pharmacol Ther,2018,47(8):1054-1070.DOI:10.1111/apt.14539. |
[1] | 苏海霞, 付兆媛, 高永泽, 尉戎戎, 钟建春. 5-羟色胺与腹泻型肠易激综合征相关性及中医药调控研究进展[J]. 中国全科医学, 2023, 26(21): 2678-2685. |
[2] | 胡佳艳, 吕咪, 王凤云. 抗生素对肠易激综合征的影响及机制探讨[J]. 中国全科医学, 2023, 26(21): 2666-2672. |
[3] | 侯雨君, 赵映, 蒋慧灵, 谭玉, 张薇, 李瑛, 郑倩华. 肠易激综合征内脏敏感性检测与评价方法的研究进展[J]. 中国全科医学, 2023, 26(21): 2673-2677. |
[4] | 巫小玉, 万崇华, 陈莹, 阮艳琴, 翁一洁, 许小江. 肠易激综合征患者报告结局与生命质量测定特异性量表研究进展[J]. 中国全科医学, 2023, 26(18): 2268-2276. |
[5] | 秦宇宁, 赵天易, 刘凤斌, 王鑫, 曹雪, 孙铭璘, 赖科云, 邸露瑶, 葛志闪, 刘松, 邢颖, 杨蕾, 岳俐宏, 邹梅梅, 何丽云, 李洪皎. 中文版胃肠道症状评定量表对胃肠道疾病患者测量学特性研究[J]. 中国全科医学, 2023, 26(18): 2277-2285. |
[6] | 张晋东, 郑浩楠, 张涛, 段丽萍. 靶向菌群治疗对肠易激综合征患者肠道菌群影响的范围综述[J]. 中国全科医学, 2023, 26(12): 1520-1529. |
[7] | 王科凯, 杨焱麟, 周彦妮, 肖瑾, 谢欣, 吴芹萍, 陈敏. 痛泻要方拆方对腹泻型肠易激综合征大鼠脑肠肽的影响研究[J]. 中国全科医学, 2023, 26(05): 569-575. |
[8] | 石云舟, 郑晖, 陈敏, 李志刚, 余曙光. 补充与替代疗法治疗肠易激综合征的研究进展[J]. 中国全科医学, 2022, 25(15): 1807-1813. |
[9] | 陈敏, 谢欣, 石云舟, 郑晖, 吴巧凤, 周海燕, 李志刚, 余曙光. 中医药治疗腹泻型肠易激综合征的比较效果研究现状及思考[J]. 中国全科医学, 2022, 25(15): 1795-1800,F01. |
[10] | 黄虹玉, 雷甜甜, 马洪升, 胡仁伟, 杨锦林. 以巨大足部溃疡为表现的坏疽性脓皮病伴克罗恩病一例报道并文献复习[J]. 中国全科医学, 2022, 25(15): 1906-1909. |
[11] | 叶坤, 雷敏, 谢欣, 郑晖, 陈敏, 余曙光. 基于网络药理学与分子对接技术探讨黄芪建中汤治疗腹泻型肠易激综合征的作用机制研究[J]. 中国全科医学, 2022, 25(15): 1814-1824. |
[12] | 吴澎泞, 熊帅, 蒋晓涵, 张怡, 梁超, 陈敏. 基于5-羟色胺治疗肠易激综合征的中西医研究进展[J]. 中国全科医学, 2022, 25(15): 1800-1806. |
[13] | 王明秀, 张钧凯, 徐炜, 范晓洁, 李飞, 邓国英. 高中生肠易激综合征现状调查及影响因素研究[J]. 中国全科医学, 2022, 25(12): 1506-1511. |
[14] | 高炼, 黄晓明, 吴清明. 肠易激综合征治疗与预防的研究进展[J]. 中国全科医学, 2022, 25(09): 1148-1154. |
[15] | 孙彩云, 林征, 周美景, 顾子君, 罗丹, 王咪, 顾珺怡, 朱展慧. 炎症性肠病患者疾病获益感的潜在剖面分析[J]. 中国全科医学, 2022, 25(06): 656-662. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||